Evidence map›Paper›PMID 42087343›Full record

ReviewCancer medicine2026

Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions.

Shuang Li, Jianguo Wang, Yingjie Liu, Wenwu Cai, Weichang Zhang, Shengyun Li, Yunjian Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuang LiDepartment of Breast Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0009-0005-2507-9119
Jianguo WangDepartment of Hepatobiliary Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
Yingjie LiuCollege of Nursing and Health Innovation, University of Texas at Arlington, Arlington, Texas, USA.
Wenwu CaiDepartment of Hepatobiliary Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-0741-7266
Weichang ZhangState Key Laboratory of Cardiovascular Diseases, Center of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Shengyun LiDepartment of General Surgery, Fifth Division, The First People's Hospital of Changde City, Changde, China.
Yunjian ZhangDepartment of Breast Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0001-8457-8421

Funding

Guangzhou Municipal Nansha District Science and Technology Program Key Projects 2024MS001Special Project for Research and Development in Key areas of Guangdong Province 2025B03J0029
6 · The paper itself

Abstract

Immunotherapy is transforming breast cancer management, but it also presents new challenges for surgical and reconstructive practice. This review summarizes current evidence on immune checkpoint inhibitors, perioperative safety, and immune-related adverse events, highlighting their impact on surgical timing, postoperative recovery, and reconstructive outcomes. We also discuss interactions between implants and the tumor immune microenvironment and emphasize the need for individualized perioperative management. Finally, we identify key research gaps, including long-term toxicity, real-world surgical outcomes, and predictive biomarkers to guide reconstructive surgeons in integrating immunotherapy into multidisciplinary care.

Indexed as

Breast NeoplasmsImmune Checkpoint InhibitorsImmunotherapyMammaplastyFemaleHumansTumor MicroenvironmentImmune Checkpoint Inhibitorsbreast cancerbreast reconstructionimmune checkpoint inhibitorsimmunotherapyperioperative management

Identifiers

PMID42087343
PMCPMC13143867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.